An IIFL report quotes the management of Strides Shasun as saying that pharmaceutical benefits scheme price cuts have bottomed out. In an interview to CNBC-TV18, Shashank Sinha, MD of the company spoke about the same and gave his outlook for the future.
Jay Purohit, Technical & Derivatives Analyst at Centrum Broking Limited, says short-term traders are advised to book some profit at current levels.
In an interview to CNBC-TV18, Shashank Sinha, Managing Director of Strides Shasun spoke about the results and his outlook for the company.
In an interview to CNBC-TV18, Shashank Sinha, MD & GROUP CEO of Strides Shasun spoke about the latest happenings in his company and sector.
Strides Shasun may receive approval for Lovaza generic, which has a market size of around USD 750-800 million in the United Sates and could make upto USD 200 million annually for the company. There has been a lot of buzz around pending application for Omega 3 which is the generic version of Lovaza, Shashank Sinha, MD & Group CEO of Strides Shasun told CNBC-TV18.
Competition Commission of India (CCI) approves Scheme of Arrangement between Strides Shasun, Sequent Scientific and Solara Active Pharma Sciences. In an interview to CNBC-TV18, Manish Gupta, CEO of Sequent Scientific spoke about the same.
Going forward, the pharma company is going to to focus on its B2C business and the high cash generating verticals, he says.
There was some regulatory overhangs post Strides-Mylan Agila transaction, says Arun Kumar, Executive VC & MD of Strides Shasun.
In an interview to CNBC-TV18, Shashank Sinha, Group CEO of Strides Shasun spoke about the results and his outlook for the company.
In an interview to CNBC-TV18, Arun Kumar, Founder & MD of Strides Shasun says that the pharma industry lacks trust now as more and more issues with regulators come to light.
In an interview to CNBC-TV18, Arun Kumar, Executive VC and MD of Strides Shasun said the company may sell off its API unit after enhancing its value.
Third quarter performance was hit due to floods in Chennai but there has been a strong pullback in the last quarter, he said, adding growth in business from regulated markets like Australia and the US have helped, said Arun Kumar, Executive VC & MD at Strides Shasun.
The growth trajectory is very strong going forward and the company has all the necessary engines to grow the business at 20-25 percent CAGR, said Arun Kumar, MD, Strides Shasun.
Abhaya Kumar, MD at Shasun Pharmaceuticals said the company's merger with Strides will be completed as soon as court approvals of the latter are in place. He is sure the merged entity will be effective from April 1 2015 itself.
The new business will operate under Arrow Pharma and sell 140 generic drugs. The transaction will be financed by internal accruals and debt financing. The acquisition will be EPS accretive immediately.
Strides Arcolab has a fairly strong organic growth strategy in place at the moment, says Group CEO & VC Arun Kumar.
Given the fact that US gets 35 percent of its drugs from India, the regulator is only doing its job in looking closely at not just India's, but other countries‘ pharma units too, adds Ramesh Adige, former executive director, Ranbaxy.
Strides Arcolab‘s subsidiary Agila Biotech has signed a joint venture agreement with US-based Pfenex for developing, manufacturing and commercializing six biosimilar products for the global market
Group CFO of Strides Arcolab TS Rangan tells CNBC-TV18 that the company is betting on Agila to drive growth in FY13.
Strides Arcolab aims to use the funds received through the sale of its Southeast Asian and Australian units to repay foreign currency convertible bondholders and reduce the debt, says group chief executive and vice chairman Arun Kumar.
In an interview with CNBC-TV18, Arun Kumar, Vice Chairman and MD, Strides Arcolab said Polymyxin is a small molecule, but currently it is in the shortage list of products. He further said the company will grow 30-35% in the current year.
Strides Arcolab received a nod by the US FDA for an Oncology unit in Bengaluru. Arun Kumar, group CEO and vice chairman of Strides Arcolab, in an exclusive interview with CNBC-TV18 shares that the company expects approvals on approximately USD 4-5 billon product filings in the next few weeks.
Stride Arcolab has declared its first quarter results. The company's Q1 consolidated net profit was up 2.26% at Rs 40.7 crore versus Rs 39.8 crore. For 2011, he says, “A median EBITDA of 21% is the one we are looking at the increased sales of Rs 2,200 crore.”
In an interview with CNBC-TV18, Arun Kumar, Group CEO and Vice Chairman, Strides Arcolab spoke on the development and the way forward for the company.
Stride Arcolab announced it Q3 results for FY11. The company reported a consolidated net profit of Rs 122.4 crore for the year ended 2010 as against Rs 109.7 crore in previous year.